Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-13 combination regimens in advanced malignant solid tumors
CTR20251473Phase 2Active
- Sponsor
- Shanghai Yifeng Biotechnology
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of K-13 in Nonhematologic neoplasms, sponsored by Shanghai Yifeng Biotechnology. Started Apr 2025; status: active.
02
Drugs
K-13
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251473.